Impact of Systemic Glucocorticoids on Breast Cancer Risk

Overview of Systemic Glucocorticoids and Breast Cancer Link

Systemic glucocorticoids (GCs) are steroid hormones widely utilized in clinical settings for their anti-inflammatory and immunosuppressive properties. Commonly prescribed for conditions such as asthma, rheumatoid arthritis, and autoimmune disorders, their long-term use has raised concerns regarding potential adverse effects, including an increase in cancer risk. This article aims to explore the impact of systemic glucocorticoids on breast cancer risk, synthesizing findings from recent epidemiological studies and clinical research.

The link between glucocorticoids and cancer risk has been an area of active inquiry, with studies suggesting both potential carcinogenic and protective effects. On one hand, GCs can lead to immunosuppression, which may facilitate tumor growth by allowing cancer cells to evade immune surveillance. Conversely, some research indicates that GCs may inhibit certain cancer-promoting pathways, particularly in breast tissue. This duality necessitates a comprehensive understanding of how glucocorticoid therapy influences breast cancer risk among different populations, particularly in women undergoing long-term treatment.

Study Design and Methodology for Glucocorticoid Analysis

A nationwide case-control study conducted in Denmark serves as a foundational analysis for understanding the relationship between systemic glucocorticoid use and breast cancer risk. This research included women diagnosed with invasive breast cancer between 2001 and 2018, matched with a control group based on age and calendar time. A critical aspect of the study design involved using prescription registries to identify glucocorticoid exposure and categorize participants into ever users and long-term users.

Table 1: Study Population Characteristics

This study utilized conditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between glucocorticoid use and breast cancer risk, adjusting for confounding variables such as comorbidities and other medication usage. By stratifying the analysis based on breast cancer subtype, stage, and hormonal receptor status, the study aimed to elucidate the nuanced effects of glucocorticoid exposure on breast cancer development.

Key Findings on Glucocorticoids and Breast Cancer Risk

The findings from the Danish study indicated no significant association between ever use of systemic glucocorticoids and breast cancer risk [OR = 1.00 (0.98—1.03)]. However, long-term glucocorticoid use (defined as filling prescriptions equivalent to ≥ 1000 defined daily doses) was associated with a decreased risk of breast cancer [OR = 0.87 (0.77—0.97)], suggesting a potential protective effect. The analysis revealed a slight dose-response relationship, indicating that higher cumulative doses of glucocorticoids might be linked to a lower risk of breast cancer.

Interestingly, the associations remained consistent across various tumor subtypes and estrogen receptor statuses. This finding challenges the perception that glucocorticoids uniformly increase cancer risk and emphasizes the need for a nuanced understanding of their role in breast cancer etiology.

Table 2: Association Between Glucocorticoid Use and Breast Cancer Risk

These results underscore the importance of considering both the duration and cumulative exposure of glucocorticoids when evaluating their relationship with breast cancer risk.

Implications of Long-term Glucocorticoid Use on Health

Long-term glucocorticoid therapy presents a complex landscape of health implications, particularly concerning cancer risk. While some studies suggest a protective effect against certain types of breast cancer, the overall impact of glucocorticoids on health remains a topic of ongoing research.

Key implications include:

1. Immunosuppression: Chronic use of glucocorticoids can impair the immune system, potentially increasing susceptibility to infections and malignancies due to reduced immune surveillance.
2. Metabolic Effects: Glucocorticoids are known to induce insulin resistance and metabolic dysfunction, which are risk factors for various cancers, including breast cancer.
3. Hormonal Interactions: The interaction between glucocorticoids and sex hormones may influence breast cancer development, particularly in estrogen-sensitive tissues.
4. Individual Variability: The effects of glucocorticoids can vary widely among individuals based on genetic, environmental, and lifestyle factors, necessitating personalized treatment approaches.

These considerations highlight the need for careful monitoring and evaluation of patients on long-term glucocorticoid therapy, particularly concerning their cancer risk and overall health outcomes.

Future Research Directions in Glucocorticoid and Cancer Studies

Future research on glucocorticoids and cancer risk must address several critical areas:

1. Longitudinal Studies: Conducting long-term cohort studies to evaluate the effects of chronic glucocorticoid use on breast cancer incidence, survival, and recurrence.
2. Mechanistic Studies: Investigating the biological mechanisms underlying the dual effects of glucocorticoids on tumor promotion and suppression, particularly in breast tissue.
3. Subgroup Analyses: Performing detailed subgroup analyses to identify specific populations at increased risk for breast cancer associated with glucocorticoid use.
4. Personalized Medicine: Developing personalized treatment plans that consider individual risk factors and the potential benefits versus risks of glucocorticoid therapy.

By addressing these areas, researchers can enhance our understanding of glucocorticoids in the context of cancer and improve clinical outcomes for patients requiring these therapies.

FAQ

What are systemic glucocorticoids? Systemic glucocorticoids are steroid hormones used to reduce inflammation and suppress the immune system, commonly prescribed for various medical conditions, including autoimmune diseases and allergies.

How do glucocorticoids affect breast cancer risk? Research shows that long-term glucocorticoid use may be associated with a decreased risk of breast cancer, although their effects can vary based on individual factors and the specific type of cancer.

What are the health implications of long-term glucocorticoid use? Long-term glucocorticoid therapy can lead to immunosuppression, metabolic changes, and potential interactions with hormonal pathways, all of which may influence cancer risk and overall health.

What future research is needed in this area? Future studies should focus on longitudinal data, mechanisms of action, subgroup analyses, and personalized treatment approaches to better understand the relationship between glucocorticoids and cancer risk.

References

1. Cairat, M., Olesen, M., Olivier, E., Pottegård, A., & Hicks, B. (2025). Systemic glucocorticoids and the risk of breast cancer in a large nationwide case–control study. Breast Cancer Research, 6, 21. doi:10.1186/s13058-025-02071-0 Link

2. Koh, E. H., Ewing, S. K., Sigurdsson, S., Gudnason, V., Hue, T. F., Vittinghoff, E., Ohlsson, C., Tivesten, Å., Grahnemo, L., Yuen, T., Zaidi, M., Rosen, C. J., & Schwartz, A. V. (2024). Higher FSH Level Is Associated With Increased Risk of Incident Hip Fracture in Older Adults, Independent of Sex Hormones. Journal of Clinical Endocrinology and Metabolism, 56, 2192. doi:10.1210/clinem/dgae690 Link

3. Pietrock, C. (2025). Diffusion weighted imaging-based differentiation of arteritic and non-arteritic anterior ischemic optic neuropathy. BMC Medical Imaging, 41. doi:10.1186/s12880-025-01780-4 Link

4. Parashar, R., Mishra, S., Raghuwanshi, P., Goyal, A., Joshi, R., Joshi, A., Chouhan, S., Hulke, S. M., Mukherjee, S., & Nema, S. (2025). A collaborative study on rehabilitating altered pulmonary functions of COVID-19 survivors with selective yoga regime. Journal of Family Medicine and Primary Care, 14(9), 2192. doi:10.4103/jfmpc

5. Bilgin, E. (2025). Current application, possibilities, and challenges of artificial intelligence in the management of rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. Therapeutic Advances in Musculoskeletal Disease, 18. doi:10.1177/1759720X251343579 Link